<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567577</url>
  </required_header>
  <id_info>
    <org_study_id>AP301-II-002</org_study_id>
    <nct_id>NCT03567577</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS</brief_title>
  <official_title>Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apeptico Forschung und Entwicklung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apeptico Forschung und Entwicklung GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IIb, randomized, placebo-controlled, double-blind, dose escalation study will&#xD;
      assess the local and systemic safety of 7 days orally inhaled sequential multiple ascending&#xD;
      doses of solnatide in patients with pulmonary permeability oedema and moderate-to-severe ARDS&#xD;
      and review potential efficacy endpoints for a future phase III pivotal trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint: Any cause death</measure>
    <time_frame>Randomisation - day 28</time_frame>
    <description>Primary Safety Endpoint: Composite endpoint including any cause death at day 28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoint: Drug-related adverse events</measure>
    <time_frame>Randomisation - day 14</time_frame>
    <description>Primary Safety Endpoint: Composite endpoint including drug-related adverse events through day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoint: All adverse events</measure>
    <time_frame>Randomisation - day 28</time_frame>
    <description>Primary Safety Endpoint: Composite endpoint including all adverse events through day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EVLWI</measure>
    <time_frame>baseline - day 7</time_frame>
    <description>Change in extravascular lung water index (EVLWI) as assessed with a validated bedside measurement (measurement with the PiCCO® system)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PVPI</measure>
    <time_frame>baseline - day 7</time_frame>
    <description>Change in pulmonary vascular permeability index (PVPI) as assessed with a validated bedside measurement (measurement with the PiCCO® system)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ventilatory settings</measure>
    <time_frame>baseline - day 14</time_frame>
    <description>Composite endpoint including ventilation mode, ventilation pressures (ventilatory plateau pressure, positive end expiratory pressure, peak inspiratory pressure, mean airway pressure, peak airway pressure, driving pressure), tidal volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Murray lung injury score</measure>
    <time_frame>baseline - day 7</time_frame>
    <description>Murray lung injury score is composed of four components: 1) chest radiograph; 2) hypoxaemia score; 3) PEEP and 4) static compliance of respiratory system. The values of the total score may range from 0 to 4. Lower values indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation ratio (PaO2 / FiO2 ratio)</measure>
    <time_frame>baseline - day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>baseline - day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days (VFD)</measure>
    <time_frame>baseline - day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization and in ICU</measure>
    <time_frame>baseline - day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>Solnatide 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solnatide 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solnatide 125mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0,9% saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solnatide 25 mg powder for reconstitution for solution for inhalation</intervention_name>
    <description>Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.</description>
    <arm_group_label>Solnatide 125mg</arm_group_label>
    <arm_group_label>Solnatide 5mg</arm_group_label>
    <arm_group_label>Solnatide 60mg</arm_group_label>
    <other_name>AP301</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline Solution</intervention_name>
    <description>Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent&#xD;
&#xD;
          2. Male or female ≥18 years of age.&#xD;
&#xD;
          3. Patient has been admitted to an ICU, is mechanically ventilated (according to the&#xD;
             ventilation and weaning protocol in Appendix I) and stable in this condition for at&#xD;
             least 8 hours.&#xD;
&#xD;
          4. Moderate-to-severe ARDS diagnosis as defined by the Berlin Definition:&#xD;
&#xD;
               -  Onset of ARDS within 1 week of a known clinical insult or new or worsening&#xD;
                  respiratory symptoms.&#xD;
&#xD;
               -  Bilateral opacities not fully explained by effusions, lobar/lung collapse, or&#xD;
                  nodules.&#xD;
&#xD;
               -  Respiratory failure not fully explained by cardiac failure or fluid overload&#xD;
                  (origin of oedema).&#xD;
&#xD;
               -  PaO2/FiO2 ≤ 200 mm Hg with Positive End-Expiratory Pressure (PEEP) ≥5 cm H2O.&#xD;
&#xD;
          5. ARDS diagnosis not older than 48 hours.&#xD;
&#xD;
          6. Extravascular lung water index (EVLWI) ≥ 10 ml/PBW as assessed with a validated&#xD;
             bedside measurement (single indicator transpulmonary thermodilution measurement with&#xD;
             the PiCCO® system).&#xD;
&#xD;
          7. Patient who meets criteria for extensive hemodynamic monitoring as per international&#xD;
             intensive care medicine standards.&#xD;
&#xD;
          8. For patients that are temporarily unable to consent (e.g. comatose patients) a&#xD;
             subsequent informed consent has to be provided.&#xD;
&#xD;
          9. Male and Female (WOCBP) patients using adequate contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically relevant allergies or idiosyncrasies to solnatide.&#xD;
&#xD;
          2. Known use of any other investigational or non-registered drug within 30 days prior to&#xD;
             study enrolment.&#xD;
&#xD;
          3. Severe state of septic shock with a Mean Arterial Pressure (MAP) ≤ 65 mm Hg and a&#xD;
             serum lactate level &gt; 4 mmol/L (36 mg/dL) despite adequate volume resuscitation.&#xD;
&#xD;
          4. An underlying clinical condition that, in the opinion of the Investigator, would make&#xD;
             it very unlikely for the patient to be successfully weaned from ventilation due to&#xD;
             severe underlying diseases (e.g. severe malnutrition, severe neurological diseases,&#xD;
             pulmonary fibrosis or COPD).&#xD;
&#xD;
          5. Extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any&#xD;
             form of extra-corporeal lung support. In no way are patients to be denied or delayed&#xD;
             these procedures to avoid exclusion from the study.&#xD;
&#xD;
          6. Neutrophil count &lt; 0.3 x 109/L.&#xD;
&#xD;
          7. Cancer treatment (chemotherapy or biological) or therapy with other immunosuppressive&#xD;
             agents for organ transplantation within 2 weeks.&#xD;
&#xD;
          8. Cachexia (BMI &lt; 18.5 kg/m2).&#xD;
&#xD;
          9. Cardiogenic pulmonary oedema diagnosed by echocardiography or pulmonary artery&#xD;
             catheter.&#xD;
&#xD;
         10. Severe skin burns involving more than 15% of body surface.&#xD;
&#xD;
         11. Subjects who are extremely unlikely to survive more than 48 hours due to the acute&#xD;
             conditions of the patient in the opinion of the Investigator.&#xD;
&#xD;
         12. Subjects transferred from a hospital not participating in this study who are already&#xD;
             planned to be re-transferred during the observation period.&#xD;
&#xD;
         13. Subjects who are not expected to survive the next month because of an underlying&#xD;
             uncorrectable medical condition or a do not resuscitate order.&#xD;
&#xD;
         14. Women known to be pregnant, lactating or having a positive or indeterminate pregnancy&#xD;
             test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernhard Fischer, Prof. Dr.</last_name>
    <phone>0043-664143</phone>
    <phone_ext>2919</phone_ext>
    <email>b.fischer@apeptico.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roman Ullrich, Prof. Dr.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Univ.-klinik f. Herz-, Thorax-, Gefäßchirurgische Anästhesiologie und lntensivmedizin, Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
      <phone>0043-664143</phone>
      <phone_ext>2919</phone_ext>
      <email>b.fischer@apeptico.com</email>
    </contact>
    <investigator>
      <last_name>Michael Schörghuber, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik für Innere Medizin / Gem. Einrichtung für Intensiv- und Notfallmedizin/GE Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Joannidis, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesia, General Intensive Care and Pain Control,Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
      <phone>0043-664143</phone>
      <phone_ext>2919</phone_ext>
      <email>b.fischer@apeptico.com</email>
    </contact>
    <investigator>
      <last_name>Roman Ullrich, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Anaesthesiologie, Klinikum der Universität München, Campus Großhadern</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
    </contact>
    <investigator>
      <last_name>Sandra Frank, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Operative Intensivmedizin und Intermediate Care</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz</last_name>
    </contact>
    <investigator>
      <last_name>Tim-Philipp Simon, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Operative Intensivmedizin, Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
    </contact>
    <investigator>
      <last_name>Christian Putensen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Schleswig-Holstein, Campus Kiel,</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
    </contact>
    <investigator>
      <last_name>Norbert Weiler, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesiologie / Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
    </contact>
    <investigator>
      <last_name>Erik Hartmann, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Klinik und Poliklinik für Anästhesiologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Fischer, Doz.</last_name>
    </contact>
    <investigator>
      <last_name>Markus Kredel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peptide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

